Reckitt Benckiser Share Discussion Threads

[lobby ludd] 01/3/2010 14:27

Yes, thru £35 now.

[philo124] 12/2/2010 16:54

New Highs coming!

[philo124] 10/2/2010 19:06

Very good indeed, especially the DIVI!

[batman9] 10/2/2010 08:21

Well done Bart - another solid set of results.

[batman9] 24/12/2009 09:15

Merry Christmas to all on the RB. board.

[gac100] 19/11/2009 09:06

raspberrypicker, no problem, its a quiet board, weeks can go by without a post.

I'm not a short term trader, so don't know about RB's price today, other than obviously "Up" ... I guess much will depend on if/when RB release any kind of RNS.

[raspberrypicker] 19/11/2009 08:21

Gac

My apologies but very quiet on here cosidering.
Where do you think the share price heading today?

[gac100] 19/11/2009 08:04

raspberrypicker, you're only 11 hours late ;-) [see post 112 above]

[raspberrypicker] 19/11/2009 07:59

Reckitt Benckiser Group PLC (RB.LN) is close to announcing an international deal, and "well-placed sources" say the most obvious candidate is Colgate- Palmolive Co. (CL), The Telegraph in London reported Wednesday. The paper says other companies mentioned as a target by Reckitt include SSL International ( SSL.LN,) a consumer-goods company like Reckitt and Colgate-Palmolive. "The theory is that any deal between Reckitt and Colgate-Palmolive would have to be structured as a merger as they are roughly the same size," The Telegraph said.Colgate-Palmolive told Fox Business Network that the company doesn't comment on market rumors.

Full story at Reckitt-merger-with-Colgate-said-to-be-close.html

-Dow Jones Newswires; 212-416-2900

[gac100] 18/11/2009 21:46

The NYSE contacted Colgate-Palmolive Company (NYSE: CL) in view of the unusual market activity in the stock today. The company stated that its policy is not to comment on unusual market activity. Shares rose nearly 4% in the final hour of trading on heavy volume.

[gac100] 18/11/2009 21:01

Telegraph reporting that Reckitt is close to announcing a "multi-billion pound cross-border transaction."

"well-placed sources" put Colgate-Palmolive top of the list with any deal structured as a merger.



Colgate Palmolive (CL 86.52, +3.68) this evening

[petethehippy] 13/11/2009 14:12

Where is this one going?
3000 is a key support point for this one.
Will it just follow the market blindly?
The descending triangle is squeezing the volatility.. should burst out one of the other pretty soon.

[batman9] 29/9/2009 08:19

Deutsche ups its target price on Reckitt Benckiser, rated buy, to 3500p from 3300p

[batman9] 05/8/2009 10:57

On 4/8/09 RBOS has a buy and new target of £32.25 for RB.

[batman9] 13/7/2009 18:06

P/E 15.1 for end 2009 - Panmure Gordon target of £30.25.
Still a little upside with oil price dropping - FTSE100 investors will turn to RB.

[bonzo1] 07/7/2009 14:59

coming off nicely now - p/e 16-17. Think they have a fair bit to fall from these heady heights.....

[bonzo1] 07/7/2009 12:09

£29 must be time to short big time......

[kellymcclean] 24/3/2009 11:27

There's a line of resistence on the monthly chart, which has been touched three times and bounced straight back down. Looking at momentum indicators like Stochastic, there is a sell signal fund suggesting the next move will be down. We already have had a sell signal on the MACD again indicating that the next move will be down.

So all of these things combined, the next price move on Reckitt Benckiser is more likely to be down than up.

You can watch a video of the charts described above "FTSE stocks - one to buy and one to sell" at

[luderitz] 24/2/2009 23:34

Bimey this one's on the dive...but there again it does move about a bit.

[brain smiley] 16/2/2009 09:01

£28 now!

[brain smiley] 13/2/2009 16:29

Looks like the suboxone issue isn't a probelm - already factored into RB profit forecasts ,and the brokers say buy.

Royal Bank of Scotland

Long term (12 months): Buy
Target price: £32.00 (from £31.00)
Reason: Change of forecast

In contrast to the disappointing run of FMCG results, Reckitt's numbers exceeded expectations. Though the 2009 targets are understandably cautious in the current environment, we see them as a base from which to build as the year unfolds. We raise our price target from 3100p to 3200p and reiterate our Buy recommendation.

Results ahead of expectations
Reckitt's 4Q results were ahead of our expectations on all the key metrics. Underlying sales rose 8% (+7% forecast); operating margin was up 40bp (+20bp forecast); and net income increased 35% (+24% forecast), helped by a significantly more favourable currency impact. The dividend has been raised 45% to 80p (70p forecast), in part reflecting a decision to prioritise dividends over share buy backs in the current environment.

Outperforming in a more challenging environment
While 4Q saw the core HPC business slow, Reckitt continues to outpace its markets comfortably. We expect a further deceleration in 2009 as market volumes weaken and pricing unwinds, but see the group's cautious 2009 guidance (+4% underlying sales and +8-10% constant currency net income) as very achievable. Indeed, we would not be surprised to see these targets raised as the year progresses.

Suboxone a drag on 2010
The loss of orphan drug status for Suboxone is now looming into view, and its recent success has only exacerbated the likely profit impact next year once generic competition hits. However, this appears to be fully reflected in forecasts, while the base business continues to deliver upside surprises.

Still our pick in the European FMCG world
We believe the consistency and strength of the group's performance continue to merit a premium PE vs its European and US peers, which is not currently evident in the rating. We raise our price target from 3100p to 3200p and reiterate our Buy recommendation.